Catalyst Crew Technologies Assigns Venezuelan Patents to Subsidiary as Part of Global IP Strategy

Catalyst Crew Technologies Corp. announced the assignment of certain intellectual property assets to its wholly-owned Venezuelan operating subsidiary, Inversiones Long 33, C.A. The intellectual property, previously held by CEO Dr. Kevin Rodan Levy, consists of three patents registered in Venezuela covering proprietary technologies referred to as CardioAI, PulmoAI, and NeuroAI. These technologies are designed to support data-driven healthcare analytics, predictive modeling, and clinical decision-support applications.

This assignment represents a continued step in the Company's effort to align its intellectual property with its operating structure, positioning the subsidiary to serve as the primary development and commercialization vehicle for its technology platform in the region. The Company believes that consolidating its intellectual property at the operating level enhances strategic flexibility, supports regulatory alignment, and may facilitate future partnerships, licensing opportunities, and regional expansion initiatives. In addition, the Company intends to pursue expanded intellectual property protection for its technologies in additional jurisdictions worldwide, as practical, in support of long-term platform development and potential international deployment.

Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated that aligning intellectual property within the operating structure is an important step as the company continues building its platform. Establishing a clear foundation around core technologies allows the company to move forward with development, partnerships, and, where appropriate, broader intellectual property protection strategies across additional markets. The Company continues to advance the development of its digital health and artificial intelligence platform, with a focus on scalable healthcare solutions, including telehealth infrastructure, remote patient monitoring, and advanced healthcare analytics designed to improve access, efficiency, and care coordination.

For more information, please visit https://catalystcrewai.com or review the Company's filings with the U.S. Securities and Exchange Commission at https://www.sec.gov. The Company is a development-stage enterprise and has not generated revenues from its newly announced business direction. There can be no assurance that the Company will successfully implement its business plan, complete acquisitions, secure financing, obtain regulatory approvals, or generate revenues. Any investment decision should be made solely on the basis of information contained in the Company's filings with the U.S. Securities and Exchange Commission and other publicly available documents.